Regnerative medicine developer Frequency Therapeutics has set the range for an initial public offering that will raise $107m if it floats at the high end.

Xinyi Biotech and Legend Star helped supply xenotransplantation technology startup Qihan Biotech with $25.5m to follow $7.8m raised last year.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Cash Capital co-led a series A for Vision Medicals, co-founded by faculty at the Yunnan Province Key Laboratory for Gene Editing.

ETH Zurich’s Versantis picked up series B funding from Zürcher Kantonalbank among other returning investors to bring its total to $20.6m.

Merck & Co has contributed to Themis’ series D round after signing a strategic partnership agreement last month to develop vaccines for undisclosed diseases.

Boundless Bio, which is developing treatments focusing on extrachromosomal DNA, has raised $46.4m from investors including Alexandria Venture Investments.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

SE Health featured in an oversubscribed round telemedicine provider Maple announced alongside an investment by Royal Bank of Canada, the deals totalling $14.5m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.